Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT

• Status: Recruiting
• Trial end date: 2020-11-30
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8hr thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shehnoor Azhar
• Collaborator: Federal Task Force on Science & Technology notified by Government of Pakistan
• Treatments: Azithromycin; Hydroxychloroquine; Oseltamivir

Criteria

Inclusion Criteria:

1. Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result

2. Either gender

3. Symptomatic for example fever, dry Cough, difficulty to breathe

Exclusion Criteria:

1. Confirmed absence of SARS-CoV-2 (COVID-19) infection by a negative test result

2. Have chronic conditions such as heart disease, liver and kidney failure

3. Pregnant or currently lactating

4. Immunocompromise and/or systemic disease(s)

5. On other antiviral drugs

6. History of allergy to any of the drugs to be administered in this study